RECRUITING

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.

Official Title

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers (CHANCES)

Quick Facts

Study Start:2024-01-02
Study Completion:2031-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06295965

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Subjects who have or have had ovarian, peritoneal, or fallopian tube carcinoma who have a life expectancy of greater than 6 months and:
  2. * Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy
  3. * Subjects who have or have had a solid tumor diagnosis and any of the following:
  4. * At least 4 months of exposure to a PARP inhibitor
  5. * Diagnosis of a blood disorder including, but not limited to, clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm
  1. * Individuals with a life expectancy of less than 6 months

Contacts and Locations

Study Contact

Swisher Lab Research Coordinators
CONTACT
206-616-8927
swisherlabrc@uw.edu

Principal Investigator

Elizabeth Swisher
PRINCIPAL_INVESTIGATOR
Fred Hutch/University of Washington Cancer Consortium

Study Locations (Sites)

Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109
United States

Collaborators and Investigators

Sponsor: University of Washington

  • Elizabeth Swisher, PRINCIPAL_INVESTIGATOR, Fred Hutch/University of Washington Cancer Consortium

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-01-02
Study Completion Date2031-12-31

Study Record Updates

Study Start Date2024-01-02
Study Completion Date2031-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Ovarian Carcinoma
  • Recurrent Primary Peritoneal Carcinoma
  • Recurrent Malignant Solid Neoplasm
  • Clonal Cytopenia of Undetermined Significance
  • Clonal Hematopoiesis
  • Idiopathic Cytopenia of Undetermined Significance
  • Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder
  • Ovarian Carcinoma
  • Myeloid Neoplasm Post Cytotoxic Therapy